ENGOT-en23 / PREVENTER

About this trial

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 (sacituzumab tirumotecan) live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

Patient Profile

In participants at least 18 years of age with endometrial cancer who have previously received both systemic, platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy, either
separately or in combination.

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	ENGOT-en23 / PREVENTER
Number:	23-04
Full Title:	A Phase 3, Randomized, Active-controlled, Open-label, Multicentre Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095).

Principal Investigator:	Dr. Dearbhaile Collins
Type:	Collaborative
Sponsor:	MSD
Recruitment Started:	Global: December 2023 Ireland: June 2024

Global Recruitment Target:	710
Ireland Recruitment Target:	15